Chronisch Lymphatische Leukämie Guidline and Quality indicator - Local Development build (v0.2.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

• Narrative Content
• XML
• JSON

: Erstlinienterapie mit BCL2-Inhibitor bei CLL - JSON Representation

Active as of 2025-01-16

Raw json | Download

{
  "resourceType" : "ActivityDefinition",
  "id" : "ErstlinieMitBCL2beiCLL",
  "meta" : {
    "profile" : [
      🔗 "https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/StructureDefinition/drug-administration-action"
    ]
  },
  "text" : {
    "status" : "extensions",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: ActivityDefinition ErstlinieMitBCL2beiCLL</b></p><a name=\"ErstlinieMitBCL2beiCLL\"> </a><a name=\"hcErstlinieMitBCL2beiCLL\"> </a><a name=\"ErstlinieMitBCL2beiCLL-en-US\"> </a><p><b>knowledgeCapability</b>: computable</p><p><b>knowledgeRepresentationLevel</b>: structured</p><p><b>url</b>: <a href=\"ActivityDefinition-ErstlinieMitBCL2beiCLL.html\">ActivityDefinition Erstlinienterapie mit BCL2-Inhibitor bei CLL</a></p><p><b>version</b>: Langversion 2.01</p><p><b>name</b>: ErstlinieMitBCL2beiCLL</p><p><b>title</b>: Erstlinienterapie mit BCL2-Inhibitor bei CLL</p><p><b>status</b>: Active</p><p><b>experimental</b>: false</p><p><b>subject</b>: <span title=\"Codes:{http://hl7.org/fhir/fhir-types Patient}\">Patient</span></p><p><b>date</b>: 2025-01-16 09:02:23+0000</p><p><b>publisher</b>: https://www.leitlinienprogramm-onkologie.de/leitlinien/s3-leitlinie-zur-diagnostik-therapie-und-nachsorge-fuer-patienten-mit-einer-chronischen-lymphatischen-leukaemie-cll</p><p><b>description</b>: </p><div><p>Erstlinienterapie mit BCL2-Inhibitor bei CLL</p>\n</div><p><b>kind</b>: MedicationRequest</p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>product</b>: <span title=\"Codes:{http://snomed.info/sct 725567006}\">B-cell lymphoma 2 inhibitor</span></p></div>"
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-knowledgeCapability",
      "valueCode" : "computable"
    },
    {
      "url" : "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-knowledgeRepresentationLevel",
      "valueCode" : "structured"
    }
  ],
  "url" : "https://www.medizin.uni-greifswald.de/fhir/guideline/cll/ActivityDefinition/ErstlinieMitBCL2beiCLL",
  "version" : "Langversion 2.01",
  "name" : "ErstlinieMitBCL2beiCLL",
  "title" : "Erstlinienterapie mit BCL2-Inhibitor bei CLL",
  "status" : "active",
  "experimental" : false,
  "subjectCodeableConcept" : {
    "coding" : [
      {
        "system" : "http://hl7.org/fhir/fhir-types",
        "code" : "Patient"
      }
    ]
  },
  "date" : "2025-01-16T09:02:23+00:00",
  "publisher" : "https://www.leitlinienprogramm-onkologie.de/leitlinien/s3-leitlinie-zur-diagnostik-therapie-und-nachsorge-fuer-patienten-mit-einer-chronischen-lymphatischen-leukaemie-cll",
  "description" : "Erstlinienterapie mit BCL2-Inhibitor bei CLL",
  "kind" : "MedicationRequest",
  "code" : {
    "coding" : [
      {
        "system" : "http://snomed.info/sct",
        "code" : "432102000",
        "display" : "Administration of substance (procedure)"
      }
    ]
  },
  "productCodeableConcept" : {
    "coding" : [
      {
        "system" : "http://snomed.info/sct",
        "code" : "725567006",
        "display" : "B-cell lymphoma 2 inhibitor"
      }
    ]
  }
}